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18.2 nmol/l in the CKD patients and 74.3 ± 14.8 nmol/l in 
the  healthy subjects. The NB-UVB course increased serum 
25(OH) D by 14.0 nmol/l (95% CI 8.7–19.5) and 17.0 nmol/l (CI 
13.7–20.2), respectively. At baseline the CKD patients showed 
significantly increased CYP27B1 levels compared to the 
healthy subjects.  Conclusions: A short NB-UVB course is an 
efficient way to improve vitamin D balance in CKD patients 
on dialysis who are receiving oral vitamin D supplementa-
tion. The increased cutaneous CYP27B1 levels in the CKD pa-
tients suggest that the loss of renal activity of this enzyme is 
at least partially compensated for by the skin. 
 Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Vitamin D deficiency is a common complication in 
pre-dialysis and dialysis patients with chronic kidney 
 disease (CKD)  [1–4] . In advanced kidney disease, the 
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 Abstract 
 Background/Aims: Chronic kidney disease (CKD) patients 
on dialysis are prone to vitamin D insufficiency despite oral 
vitamin D supplementation. Here, we studied whether nar-
row-band ultraviolet B (NB-UVB) exposures improve vita-
min D balance.  Methods: 14 haemodialysis patients and 15 
healthy subjects receiving oral cholecalciferol 20 μg daily 
got nine NB-UVB exposures on the entire body. Serum 25-hy-
droxyvitamin D (25(OH)D) was measured by radioimmuno-
assay. Cutaneous mRNA expression levels of CYP27A1 and 
CYP27B1, two enzymes required for hydroxylation of vita-
min D into its active metabolite, were also measured.  Re-
sults: The baseline serum 25(OH)D concentration was 57.6 ± 
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 kidney is unable to produce 1,25-dihydroxyvitamin D 
(1,25(OH) 2 D) from 25-hydroxyvitamin D (25(OH)D) 
due to loss of renal 1α-hydroxylase (CYP27B1) activity 
 [5, 6] . An individual’s vitamin D status is best evaluated 
by measuring the level of serum 25(OH)D  [6, 7] . CKD 
patients are recommended to have a serum 25(OH)D 
concentration >75.0 nmol/l (>30.0 ng/ml)  [8] . However, 
this level is difficult to achieve using oral ergocalciferol 
supplementation for 6 months  [9] . A recent meta-analy-
sis on the use of oral vitamin D compounds in dialysis 
and non-dialysis CKD patients confirmed significant 
improvement in serum 25(OH)D concentration, but no 
effect on bone or cardiovascular outcomes were found 
 [10] .
 Artificial ultraviolet B (UVB) skin exposures are an-
other possible method of improving vitamin D balance 
because solar UVB radiation is a potent inducer of vita-
min D photosynthesis. The synthesis starts from 7-dehy-
drocholesterol in the skin and is rapidly processed into 
vitamin D. The next steps of synthesis are programmed 
in the liver and kidney, but also occur in skin keratino-
cytes. These cells have CYP27A1 (25-hydroxylase) and 
CYP27B1 (1α-hydroxylase) enzymes to hydroxylate vita-
min D to 25(OH)D and further to 1,25(OH) 2 D, which is 
the active form of vitamin D  [6, 7] . A narrow-band UVB 
(NB-UVB) course, which is widely used as treatment for 
psoriasis, increases serum 25(OH)D levels in vitamin-D-
insufficient subjects more efficiently than oral cholecal-
ciferol  [11, 12] .
 We found previously in CKD patients on haemodi-
alysis who had no oral vitamin D supplementation that 
their serum 25(OH)D levels responded rapidly to a 
3-week NB-UVB course  [13] . The 25(OH)D concentra-
tion increased by 43% and after the NB-UVB course 
none of the patients were vitamin D deficient. In the 
present study, we examined whether a similar short 
 NB-UVB course improves vitamin D balance in dialysis 
patients receiving standard oral vitamin D supplementa-
tion, i.e. cholecalciferol 20 μg daily prior to and during 
the study. In addition, we measured cutaneous messen-
ger RNA (mRNA) expression levels of CYP27A1 and 
CYP27B1.
 Materials and Methods 
 CKD Patients on Dialysis and Healthy Subjects 
 There were 32 patients in our self-care haemodialysis unit. The 
inclusion criteria for the study were: age of 18–70 years; no sun 
tanning within the 2 preceding months; Fitzpatrick skin type II–
IV, which indicates that skin does not burn easily in the sun, and 
daily use of oral cholecalciferol 20 μg (800 IU) for at least 1 month. 
14 CKD stage 5 patients on haemodialysis (6 male, 8 female, mean 
age 53.6 years;  table 1 ) meeting these criteria were enrolled in the 
study. The patients had been on dialysis for a mean of 47 (range 
9–117) months. During the study, all 14 patients received calcium 
carbonate, 12 non-calcium-containing phosphate binder, 6 cina-
calcet and 7 active vitamin D analogues. The CKD patients had 
used oral cholecalciferol 20 μg daily for a mean of 5.3 (range 1–16) 
months.
 15 hospital employees (1 male, 14 female, mean age 46.1 years; 
 table 1 ) volunteered as controls in the study. These subjects had 
used oral cholecalciferol 20 μg daily for a mean of 3.4 (range 1–24) 
months. Both groups continued to use cholecalciferol 20 μg daily 
during and after the NB-UVB course.
 The ethics committee of Tampere University Hospital approved 
the study protocol and all subjects gave an informed consent to 
participate. The authors followed the Declaration of Helsinki.
 NB-UVB Exposures 
 The study was performed between December 2011 and March 
2012. The subjects received nine NB-UVB exposures given three 
times a week on the entire body with a Waldmann UV 7001 cabin 
(Schulze & Böhm, Brühl, Germany). The NB-UVB exposures were 
given to the patients prior to dialysis. The first NB-UVB dose was 
0.19 J/cm 2 (1.11 SED), and this dose was increased according to a 
fixed protocol gradually up to 0.97 J/cm 2 (5.70 SED). One SED is 
equivalent to 10 mJ/cm² CIE (Commission Internationale de 
l’Eclairage) erythema-weighted irradiance. The mean cumulative 
dose of NB-UVB given to the CKD patients was 4.53 (range 2.97–
Table 1.  Demography, use of oral cholecalciferol before the NB-UVB course and 25(OH)D levels at baseline in 14 CKD patients on hae-
modialysis and 15 healthy subjects
  CKD patients Healthy subjects p value
  (n = 14) (n = 15)
Male/female 6/8 1/14 0.035
Age, years (mean ± SD) 53.6±12 46.1±11 0.11
Body mass index, kg/m2 (mean ± SD) 32.1±8.4 23.6±3.8 0.001
Fitzpatrick skin type II/III/IV 5/7/2 3/10/2 0.67
Use of cholecalciferol 20 μg daily before NB-UVB course, months, median (range) 2.3 (1–16) 2.0 (1–24) 0.40
Serum 25(OH)D, nmol/l (mean ± SD) 57.6±18.2 74.3±14.8 0.01
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4.75) J/cm 2 which is equivalent to 26.6 SED. In the healthy subjects, 
the mean cumulative dose of NB-UVB was 4.37 J/cm 2 (range 3.21–
4.75) which is equivalent to 25.7 SED.
 Measurement of Serum 25(OH)D Concentrations 
 Blood samples for serum 25(OH)D measurements were taken 
before the first and the ninth NB-UVB exposures, and follow-up 
samples 1 and 3 months after the NB-UVB course. The samples 
were protected from light, centrifuged and then stored at –70   °   C. 
The 25(OH)D concentration was analysed in duplicates using a 
radioimmunoassay (Immunodiagnostic Systems, Boldon, UK) as 
previously described  [13] .
 Skin Biopsies and Quantitative Real-Time PCR 
 Punch biopsies were taken from the buttocks of 10 CKD 
 patients and 13 healthy subjects before the first and the ninth 
NB-UVB exposures. The biopsies were frozen and stored at 
–70  °  C. Total RNA was isolated using TRIsure Reagent (Bioline, 
Luckenwalde, Germany), and 1 μg of RNA was reverse tran-
scribed with the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, Calif., USA) to cDNA. The 
mRNA expression levels of CYP27A1 and CYP27B1 were evalu-
ated using a LightCycler ® 2.0 system and the corresponding hu-
man Universal Probe Library Set (Roche) as previously de-
scribed  [13] .
 Statistics 
 The statistical comparison between the groups was performed 
by t test, permutation test or χ 2 test. Repeated measures were ana-
lysed using generalizing estimating equations models with the un-
structured correlation structure using bootstrap type standard er-
ror. The changes within CKD patients were analysed by applying 
a t test and a permutation test to related samples.
Table 2.  25(OH)D concentrations and levels of intact parathyroid 
hormone (PTH), haemoglobin, ionized calcium and phosphorus 
before and after a NB-UVB course in 14 CKD patients on haemo-
dialysis
  Before 
NB-UVB
After 
NB-UVB 
p value
mean ± SD mean ± SD
25(OH)D, nmol/l 57.6±18.2 71.7±17.2 <0.001
Intact PTH, pmol/l 31.8±29.0 26.7±25.6 0.11
Haemoglobin, g/l 114.2±11.3 112.3±9.2 0.39
Ionized calcium, mmol/l 1.18±0.08 1.16±0.07 0.044
Phosphorus, mmol/l 1.88±0.44 1.91±0.32 0.86
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 Fig. 1. Serum 25(OH)D concentrations before and after the NB-
UVB course in 14 CKD patients on ( a ) haemodialysis and ( b ) 15 
healthy subjects. The both groups had been receiving oral vitamin 
D substitution at a daily dose of 20 μg. The increase is significant 
(p < 0.001) in the both groups. 
Time (months)
1 2 3
25(
OH
)D 
cha
ng
e f
rom
 ba
sel
ine
 (n
mo
l/l)
–10
–5
0
5
10
15
20
25
30
35
40
 Fig. 2. A NB-UVB course given for 1 month increased serum 
25(OH)D concentration by 24.2% in 14 CKD patients on haemo-
dialysis (black dots) and by 22.8% in 15 healthy control subjects 
(open dots) receiving continuous oral vitamin D substitution. After 
the NB-UVB exposures, at 2 and 3 months from baseline, 25(OH)
D concentrations were still significantly higher than at baseline in 
the both groups. Mean values; 95% CIs are shown by bars. 
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 Results 
 Serum 25(OH)D Concentrations before and after the 
NB-UVB Course 
 The baseline serum 25(OH)D concentration was 
57.6 ± 18.2 nmol/l (mean ± SD) in the 14 dialysis patients 
( table  1 ). The serum 25(OH)D was <50.0 nmol/l in 6 
(43%) and <75.0 nmol/l in another 6 (43%) patients 
( fig. 1 ). The NB-UVB course increased serum 25(OH)D 
by 14.0 nmol/l (95% CI 8.7–19.5, p < 0.001), or 24.2% 
( fig. 1 ). Only 1 (7%) patient had serum 25(OH)D <50.0 
nmol/l. NB-UVB treatment had only marginal effects on 
the other laboratory findings ( table 2 ).
 The baseline serum 25(OH)D was 74.3 ± 14.8 nmol/l 
in the 15 healthy subjects ( table 1 ). NB-UVB course in-
creased serum 25(OH)D by 17.0 nmol/l (CI 13.7–20.2, 
p < 0.001), or 22.8% ( fig. 1 ).
 Figure 2 shows that 1 and 2 months after the NB-UVB 
course, serum 25(OH)D levels were still significantly 
higher than at baseline in the CKD patients (mean 69.8 ± 
18.1 and 64.5 ± 22.3 nmol/l; p < 0.001 and p = 0.031), and 
in the healthy subjects (88.3 ± 19.9 and 91.8 ± 19.7 nmol/l; 
p = 0.002 and p < 0.001).
 CYP27A1 and CYP27B1 mRNA Expression in the Skin 
 At baseline, the CKD patients showed decreased 
 CYP27A1 mRNA expression (p = 0.028), whereas 
 CYP27B1 mRNA expression was significantly (p = 0.003) 
increased compared to the healthy subjects ( fig.  3 a, b). 
The NB-UVB course caused a significant decrease in 
the  CYP27A1 (p = 0.018) and CYP27B1 (p = 0.010) 
mRNA expression levels in the CKD patients, and also in 
the healthy subjects (p < 0.001, p = 0.002, respectively; 
 fig. 3 a, b).
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 Fig. 3.  a CYP27A1 mRNA expression levels in skin biopsies in 
CKD patients on haemodialysis (n = 10) (left) and healthy subjects 
(n = 13) (right) before and after the NB-UVB course. Before the 
NB-UVB course the CYP27A1 levels were significantly (p = 0.028) 
lower in the CKD patients compared to healthy subjects. The NB-
UVB course caused a significant decrease in the CYP27A1 levels 
in the CKD patients (p = 0.018) and healthy subjects (p < 0.001). 
 b  CYP27B1 mRNA expression levels in skin biopsies in CKD pa-
tients on haemodialysis (n = 10) (left) and healthy subjects (n = 13) 
(right) before and after a NB-UVB course. Before the NB-UVB 
course the CYP27B1 levels were significantly (p = 0.003) higher in 
the CKD patients compared to healthy subjects. The NB-UVB 
course caused a significant decrease in the CYP27B1 levels in the 
CKD patients (p = 0.01) and healthy subjects (p = 0.002). 
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 Discussion 
 In the present study, NB-UVB exposures were given to 
14 CKD patients on haemodialysis who were receiving 
oral cholecalciferol 20 μg daily. The supplementation of 
20–25 μg of vitamin D daily has been recommended for 
older people to prevent bone fractures  [14] , and these 
amounts are also in common use in Finnish CKD patients 
on haemodialysis. Despite this supplementation, the 
mean serum 25(OH)D concentration was at baseline 
rather low, i.e. 57.6 nmol/l. In 6 (43%) dialysis patients, 
the serum 25(OH)D was <50.0 nmol/l (20.0 ng/ml), 
which can be considered as vitamin D insufficient  [15] . A 
NB-UVB course given within a 3-week period signifi-
cantly increased the serum 25(OH)D. The mean concen-
tration was 71.6 nmol/l, and only 1 patient was still vita-
min D insufficient. The increase of 25(OH)D was 24.2%, 
but this percentage is almost two times lower than in our 
previous study when the dialysis patients were not on oral 
vitamin D supplementation  [13] . To our knowledge, 
these studies are the first to show that NB-UVB exposures 
can be used to improve vitamin D balance in CKD pa-
tients on dialysis. The NB-UVB exposures were easy to 
give in connection with dialysis sessions, and one expo-
sure took only a few minutes. The NB-UVB treatment 
cabins are usually available in dermatologic outpatient 
clinics in the same hospitals as dialysis units. In our uni-
versity hospital the cost of one NB-UVB exposure is ap-
proximately 10% of one haemodialysis session showing 
that the cost is not any potential barrier to this treatment. 
Moreover, the NB-UVB doses were small. So far, this 
widely used dermatologic treatment has not shown any 
increased risk for skin cancer  [15, 16] .
 In the present study, we followed up serum 25(OH) D 
concentrations for 2 months after the NB-UVB course. 
In contrast to NB-UVB-treated healthy subjects, 
25(OH) D concentrations began to decrease in the CKD 
patients after 2 months. The more profound decrease of 
25(OH) D may be caused by the higher BMI of the CKD 
patients compared to healthy subjects and linked to 
the active metabolism of vitamin D precursors in the fat 
tissue  [7] . Though our present and previous CKD pa-
tient series were small, the observed relatively rapid de-
crease of serum 25(OH)D suggests that the CKD pa-
tients would need a longer NB-UVB course or cyclic 
NB-UVB exposures to maintain their vitamin D bal-
ance. The further limitation of the present study was that 
the dialysis patients were supplemented by only one 
dose of cholecalciferol, and a dose >20 μg daily would 
also be of interest.
 In advanced kidney disease, the kidney is unable to 
produce 1,25(OH) 2 D from 25(OH)D due to loss of renal 
CYP27B1 activity  [5, 6] . It has been shown in UVB-treat-
ed organ cultures of skin that keratinocytes are able to 
hydroxylate 25(OH)D to 1,25(OH) 2 D  [17] . The finding 
that the CYP27B1 enzyme is also outside the kidney is of 
interest with regard to oral vitamin D treatment in the 
CKD patients  [18] . In the present study, we found that 
prior to NB-UVB exposures the CKD patients had sig-
nificantly increased cutaneous mRNA expression of the 
CYP27B1 enzyme compared to healthy subjects. The in-
creased cutaneous CYP27B1 levels in the CKD patients 
supplemented with oral cholecalciferol suggest that the 
loss of renal activity of this enzyme is at least partially 
compensated for by the skin. This hypothesis was also 
supported by the previous study demonstrating that di-
alysis patients on oral vitamin D supplementation had 
enough extrarenal CYP27B1 activity to influence the se-
rum 1,25(OH) 2 D levels  [19] . Interestingly, the NB-UVB 
course caused a significant decrease in the mRNA expres-
sion of CYP27B1 and CYP27A1 in both the CKD patients 
and healthy subjects. This type of decrease can be expect-
ed because there is a very sensitive natural feedback con-
trolling mechanism caused by the UVB-induced increase 
in cutaneous vitamin D synthesis  [6, 7, 20] .
 In conclusion, the present study shows that a short 
NB-UVB course is a rapid and effective way to improve 
vitamin D balance also in those dialysis patients who have 
already had oral vitamin D supplementation. The in-
creased CYP27B1 levels in the patients suggest that the 
loss of renal activity of this enzyme is at least partly com-
pensated for by the skin.
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